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Introduction
GATA1 is an essential erythro-megakaryocytic transcription factor. 
In normal humans, alternative splicing or translation initiation site 
usage produces 2 forms of GATA1 protein: full-length (GATA1fl) and 
a truncated isoform lacking the first 83 amino acids (GATA1s) (1, 2). 
Germline GATA1 mutations that favor GATA1s expression over full-
length GATA1 (hereafter referred to as “GATA1s mutations”) were 
identified in a pedigree with congenital hypoplastic anemia and neu-
tropenia (2) and in patients with Diamond Blackfan anemia (DBA), a 
rare congenital anemia with erythroid hypoplasia (3, 4). In individu-
als with germline trisomy 21 (T21, Down syndrome [DS]), somatic 
GATA1s mutations in fetal hematopoietic progenitors promote 2 clon-
al disorders, transient myeloproliferative disease (TMD) and acute 
megakaryoblastic leukemia (AMKL) (5, 6). Notably, euploid patients 
with germline GATA1s mutations are not predisposed to leukemia.
The GATA1 N-terminus, which is absent in GATA1s, was origi-
nally named the N-terminal activation domain (NAD) by virtue 
of its ability to activate transcription in heterologous cells (1, 7). 
However, the GATA1 N-terminus is partially dispensable for hema-
topoiesis in several murine models (8–10). Gata1– embryos all die 
of profound anemia in midgestation (E10.5) (11). In contrast, mice 
with germline Gata1s mutations exhibit moderate-to-severe ane-
mia and enhanced megakaryopoiesis between E9.5 and E14.5, but 
some survive to birth, after which hematopoiesis normalizes post-
natally (12, 13). Overall, studies of human patients and genetically 
manipulated mice demonstrate that the functions of the GATA1 
N-terminus and the consequences of its loss depend on gene dos-
age, cell context, developmental stage, and species (2, 3, 9, 12–14).
Defining how the GATA1 N-terminus (or lack thereof) 
affects hematopoiesis separately or in combination with T21 
has been challenging, partly due to lack of ideal experimental 
systems. We investigated the functions of the GATA1 N-termi-
nus by analyzing induced pluripotent stem cells (iPSCs) from 
patients with GATA1s mutations and Gata1 gene–disrupted 
murine embryonic stem cells (ESCs). Both ESCs and iPSCs 
self renew in culture and generate multiple hematopoietic lin-
eages through directed in vitro differentiation (15, 16). Our find-
ings provide 2 major mechanistic insights into functions of the 
GATA1 N-terminus and pathophysiologies of human diseases 
associated with its loss. First, GATA1s mutations impair erythro-
poiesis, with hematopoietic output biased toward myeloid and 
megakaryocytic cells. Second, GATA1s binding is specifically 
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primary stromal cells of T21 or euploid subjects with WT GATA1. 
Most cells were reprogrammed using a polycistronic lentiviral 
vector encoding OCT4, SOX2, KLF4, and MYC regulated by a 
doxycycline-inducible promoter (17, 18). Early in this study, some 
lines were generated using individual retroviruses, each encod-
ing 1 reprogramming factor. We obtained similar results for each 
genotype created using different reprogramming systems. In DS-
TMD, premalignant blasts carrying the GATA1s mutation circulate 
with WT GATA1 blood cells. Reprogramming blood mononuclear 
cells from such patients generated “isogenic” groups of GATA1s 
and WT GATA1 iPSC clones (n = 2 different patients, Supplemental 
Table 1). All iPSC clones fulfilled standard quality control criteria 
impaired at erythroid target genes, implicating the N-terminus 
as a selective chromatin occupancy factor. More generally, our 
studies illustrate the utility of pluripotent stem cells as model 
systems for investigating human diseases.
Results
Generation of iPSCs. We reprogrammed peripheral blood mono-
nuclear cells from 5 DS patients with TMD caused by somatic 
GATA1s mutations and 1 euploid patient with a similar germline 
GATA1 mutation (Supplemental Table 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI75714DS1). 
Additional control iPSC lines were produced from fibroblasts or 
Figure 1. GATA1s mutations inhibit erythropoiesis from patient-derived iPSCs. (A) Flow-cytometry analysis of CD34+/–CD43+CD41+CD235+ progenitors 
within total EB cultures on day 7 of hematopoietic differentiation and (B) suspension cells released from EBs on day 12 showing mature hematopoietic lin-
eages: erythroid (CD41–CD235+), megakaryocytic (Meg, CD41+CD42+), and myeloid (CD45+CD18+). Numbers denote percentage of total cells in the indicated 
gate. (C) Frequency of CD43+CD41+CD235+ progenitor cells in EB cultures on days 7 and 8 of hematopoietic differentiation (n = 6; 17 independent experi-
ments for euploid and T21 groups, respectively). (D) Summary of distribution of lineage-committed cells in EB suspension cultures on differentiation day 
12 (n = 12; 20 independent assays for euploid and T21 groups, respectively). (E) Hematopoietic cell morphology on day 20 of differentiation cultures of iso-
genic WT GATA1 or GATA1s iPSCs. Scale bars: 50 μm. (F) Western blot of iPSC-derived hematopoietic cells. (G) DNA sequence analysis showing WT GATA1 
and a heterozygous exon 2 mutation in 2 different iPSC clones from a female with DS and TMD. (H) Isogenic lines from 2 different TMD patients were 
analyzed. Percentages of mature lineages from day-12 EB suspension cultures, as in D. (n = 6; 4 independent assays for TMD8 and TMD9, respectively).  
*P < 0.005 for myeloid and erythroid lineages (2-tailed Student’s t test).
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(CD43+CD41+CD235+) was present at similar frequencies within 
EBs of all genotypes (Figure 1, A and C). These progenitors were 
released into the medium, and by day 12, WT GATA1 control cul-
tures contained lineage-committed erythroid (CD235+CD41–), 
megakaryocytic (CD41+CD42+), and myeloid (CD45+CD18+) 
cells (Figure 1B, top row). T21/WT GATA1 iPSCs produced about 
2-fold increased proportion of erythroblasts compared with 
euploid iPSCs, as described previously (18). Euploid/GATA1s and 
T21/GATA1s progenitors exhibited severely impaired erythropoi-
esis despite retained capacity for myeloid and megakaryocytic dif-
ferentiation (Figure 1B, bottom 2 rows, and Figure 1D). May-Grün-
(Supplemental Figure 1). DNA sequencing detected the appropri-
ate GATA1 mutations and karyotypes in patient-derived iPSCs 
(Supplemental Table 1).
Loss of the N-terminus of GATA1 perturbs hematopoiesis. We 
compared the blood-forming potential of euploid and T21 iPSC 
lines with WT GATA1 or GATA1s mutations. We generated embry-
oid bodies (EBs) in defined media containing sequential combi-
nations of cytokines to induce primitive streak/mesoderm forma-
tion followed by hematopoietic specification and multilineage 
differentiation (Supplemental Figure 2 and refs. 15, 18). On days 7 
to 8 of EB differentiation, a hematopoietic progenitor population 
Figure 2. GATA1s mutations impair erythropoiesis and enhance the production of myeloid cells and megakaryocytes in iPSC-derived CD43+CD41+CD235+ 
progenitors. (A) Methylcellulose colony assays containing SCF, IL-3, EPO, GM-CSF, and (B) colony-forming megakaryocyte (CFU-Mk) assays with TPO, 
IL-3, and IL-6 of CD43+CD41+CD235+ progenitors. Results show mean values ± SEM of all lines performed in triplicate (n = 4 euploid/WT GATA1, 2 euploid/
GATA1s, 4 T21/WT GATA1, and 5 T21/GATA1s lines). (C) Methylcellulose colony assays and (D) CFU-Mk formation from CD43+CD41+CD235+ progenitors from 
2 pairs of isogenic iPSC clones with the indicated GATA1 alleles, performed as in A and B. (E) Schematic and representative flow-cytometry analysis of WT 
GATA1 and GATA1s CD43+CD41+CD235+ progenitors grown in liquid culture to preferentially support erythroid (CD71+CD235+), megakaryocyte (CD41+CD42+), 
and myeloid (CD45+CD18+) differentiation. Numbers denote percentage of total cells in the indicated gate. (F) Fold expansion of erythroid, megakaryocyte, 
and myeloid cells after 6 days in lineage-specific liquid cultures of euploid or T21 progenitors expressing WT GATA1 or GATA1s (n = 4 independent assays for 
each bar with the exception of n = 3 for euploid/GATA1s in erythroid culture, n = 5 for T21/WT GATA1 in erythroid culture, and n = 5 for T21/WT GATA1 and 
T21/GATA1s in megakaryocyte culture). *P < 0.05 (2-tailed Student’s t test).
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ent individuals, irrespective of chromosome 21 status (Figure 2A). 
Megakaryocyte colony-forming frequency and size were normal in 
GATA1s iPSCs (Figure 2B), while myeloid colony-forming potential 
was increased and myeloid colony size tended to be larger (Figure 
2A and Supplemental Figure 3). We obtained similar results com-
paring 2 sets of isogenic WT GATA1 and GATA1s iPSC lines from 
individuals with DS-associated TMD (Figure 2, C and D). Togeth-
er, the EB suspension and methylcellulose colony assays indicate 
that GATA1s inhibits erythropoiesis and enhances myelopoiesis.
Similar megakaryocyte colony formation between WT GATA1 
and GATA1s iPSC–derived progenitors suggested comparable mega-
karyocyte progenitor frequency between the 2 genotypes. However, 
collagen-based assays are not a robust method for determining 
megakaryocyte proliferative capacity. To investigate this property 
further for all lineages, we cultured EB-derived CD43+CD41+CD235+ 
progenitors on OP9 stromal cells with cytokine combinations that 
promote erythroid, megakaryocytic, or myeloid development selec-
tively (Figure 2E). In erythropoietin (EPO) and stem cell factor 
(SCF), WT GATA1 progenitors differentiated predominantly into 
CD71+CD235+ erythroblasts (Figure 2E, top panel). Under the same 
conditions, GATA1s progenitors produced a reduced proportion of 
erythroblasts, with the remainder of cells being myeloid (Figure 2E 
and not shown). Overall, erythroid expansion was approximately 
3-fold reduced by GATA1s versus WT GATA1 on a euploid back-
ground and approximately 20-fold reduced with T21 (Figure 2F). 
Thus, the GATA1s mutation overrides enhanced erythropoiesis con-
ferred by T21. In contrast with its negative effects on erythropoiesis, 
GATA1s enhanced megakaryocyte and myeloid cell expansion in liq-
uid cultures irrespective of chromosome 21 status (Figure 2F). These 
findings are consistent with previous studies showing that GATA1s 
mutations inhibit erythropoiesis and enhance fetal megakaryopoi-
esis in mouse embryos (12, 13).
Dose-dependent partial restoration of erythropoiesis by ectopic 
GATA1fl and GATA1s. In mice, mutations that decrease the expres-
sion of normal GATA1 protein impair erythropoiesis (25, 26). Thus, 
diminished levels of overall GATA1 expression may explain the 
wald-Giemsa staining revealed numerous late-stage erythroblasts 
in day-20 EB cultures from WT GATA1 iPSCs (T21 or euploid), but 
not from GATA1s iPSCs (Figure 1E).
Western blotting of EB-derived hematopoietic cells from 
euploid and T21 iPSC lines with WT GATA1 demonstrated 
predominantly full-length GATA1, but also GATA1s (Figure 
1F; see complete unedited blots in the supplemental material). 
All T21/GATA1s iPSC–derived hematopoietic cells expressed 
GATA1s, but no full-length protein. These findings occurred in 
male and female iPSCs that were hemizygous and heterozygous 
for the X chromosome–linked GATA1s mutation, respectively. 
Thus, female T21/GATA1s iPSC clones retained the same inac-
tive X chromosome as the somatic cells from which they were 
derived, consistent with prior reports that X chromosome inacti-
vation is maintained during human iPSC reprogramming (19–21). 
During the course of this study, serial Western blotting for GATA1 
showed that female GATA1s iPSC lines did not undergo reactiva-
tion of the lyonized X chromosome, which can occur during iPSC 
passage (19, 22).
Genetic and epigenetic variation between different iPSC lines 
may alter their developmental potential, including hematopoietic 
(23, 24). We controlled for this by systematically analyzing multiple 
iPSC clones from different individuals of the same relevant geno-
type (Figure 1, C and D, n = 6 GATA1s and 12 WT GATA1) and iso-
genic lines from TMD blasts (T21/GATA1s) and normal blood cells 
(T21/WT GATA1) of the same DS patients (n = 2 different subjects, 
Supplemental Table 1 and Figure 1, G and H). The GATA1s mutation 
selectively blocked erythropoiesis in all iPSC clones examined.
We next assessed the hematopoietic colony-forming potential 
of day-7 to day-9 EB-derived CD43+CD41+CD235+ progenitors 
from euploid and T21 iPSCs with WT GATA1 or GATA1s geno-
types. T21/WT GATA1 progenitors generated 2- to 3-fold increased 
proportion of erythroid colonies compared with euploid progeni-
tors (Figure 2A), as previously reported (18). In contrast, erythroid 
colony-forming potential was severely reduced in GATA1s progeni-
tors compared with WT GATA1 progenitors from iPSCs of differ-
Figure 3. Dose-dependent restoration of eryth-
ropoiesis with enforced expression of full-length 
GATA1 and truncated GATA1s. T21/WT GATA1 
and T21/GATA1s iPSC–derived CD43+CD41+CD235+ 
progenitors were transduced with lentivirus 
containing vector alone or encoding GATA1fl or 
GATA1s and cultured with EPO and SCF (n = 4 
replicates). (A) Representative flow-cytometric 
analysis after 6 days of culture. Numbers denote 
percentage of total cells in the indicated gate. (B) 
Average percentage of CD235+ erythroblasts in 
transduced (GFP+) cells after 6 days of culture. (C) 
PCR showing relative GATA1 mRNA expression 2 
days after lentiviral infection with control vector, 
GATA1fl, or GATA1s. The genotype of progenitors 
is shown on the x axis. (D) Expression of selected 
erythroid mRNAs in flow-cytometry–purified 
CD235+ infected (GFP+) cells.
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erythroblasts, ectopic GATA1s activated erythroid gene expression 
less effectively than similarly expressed GATA1fl (Figure 3, C and 
D). Thus, supraphysiologic levels of GATA1s (3- to 6-fold above nor-
mal, Figure 3C) can partially compensate for loss of the N-terminus 
to promote erythropoiesis, but are still less effective than GATA1fl.
WT GATA1 and GATA1s hematopoietic progenitor populations 
demonstrate transcriptional bias toward distinct lineages. To investi-
gate how loss of the GATA1 N-terminus affects gene expression, we 
used the Affymetrix HuGene 1.0 ST chip to compare the transcrip-
tomes of flow-cytometry–purified T21/GATA1s and T21/WT GATA1 
iPSC-derived progenitor populations (CD43+CD41+CD235+). 
Among 19,392 genes examined, 10,873 were expressed in cells 
of one or both genotypes. A total of 273 genes were differentially 
erythropoietic defect of GATA1s iPSCs. To test this, we infected 
CD43+CD41+CD235+ hematopoietic progenitors generated from 
isogenic WT GATA1 and GATA1s iPSCs with lentivirus expressing 
GFP and GATA1fl or GATA1s cDNAs. The infected cells were cul-
tured in erythroid-promoting cytokines, as in Figure 2, E and F. Most 
(~80%) of the transduced WT GATA1 progenitors differentiated 
into CD235+CD71+ erythroblasts, independent of ectopic GATA1fl 
expression (Figure 3, A and B). In GATA1s progenitors, both GATA1fl 
and GATA1s overexpression partially rescued erythropoiesis, 
although to different extents. On average, 22% and 8% of GATA1s 
progenitors transduced with GATA1fl or GATA1s, respectively, dif-
ferentiated into erythroblasts compared with less than 0.5% for 
controls. (Figure 3, A and B). In lineage-committed GATA1s mutant 
Figure 4. Global transcriptome analysis demonstrates that GATA1s mutations downregulate erythroid and upregulate myelo-megakaryocytic genes. (A) 
Mean expression values of 10,873 expressed genes in T21/GATA1s (n = 3 replicates) versus T21/WT GATA1 (n = 6 replicates) iPSC–derived CD43+CD41+CD235+ 
progenitors. 273 genes were differentially expressed between T21/GATA1s and T21/WT GATA1, with a fold change of mean expression of less than 2 (217 
genes, blue) or 2-fold or greater (56 genes, green). (B) GSEA on 273 differentially expressed genes using erythroid, megakaryocytic, and myeloid expres-
sion profiles from Novershtern et al. (30). Top: enrichment of 154 genes that were upregulated in T21/GATA1s as compared with T21/WT GATA1 progenitors 
in myeloid versus erythroid signature genes and in megakaryocytic versus erythroid genes. Bottom: enrichment of 119 downregulated genes in erythroid 
versus myeloid genes and in erythroid versus megakaryocytic genes. NES, normalized enrichment score; P values shown are from modified Kolmogorov-
Smirnov test as implemented in GSEA. (C) Heat maps showing expression levels of 2-fold or greater upregulated (top) and downregulated (bottom) genes 
in T21/GATA1s versus T21/WT GATA1 progenitors (left) as well as in lineage-committed cells (right) based on expression levels in erythroid (n = 7 replicates 
of CD34–CD71loGlyA+, 6 of CD34–CD71–GlyA+ cells), myeloid (n = 6 replicates of basophils, 5 of eosinophils, 4 of neutrophils), and megakaryocytic (n = 5 
replicates of CFU-megakaryocytes, CD34+CD41+CD61+CD45–, 7 of mature megakaryocytes, CD34–CD41+CD61+CD45–) cells from Novershtern et al. (30). Color 
scheme is row normalized from blue to red corresponding to minimum to maximum expression values in a given row, respectively. ZC3H12C, COL24A1, 
MIR221, P2RY12, PARP9, and OCIAD2 were not represented on microarrays from Novershtern et al. (30).
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expressed (Benjamini-Hochberg false discovery rate [BH‑FDR] < 
0.1; moderated t test followed by BH correction for multiple tests), 
of which 56 differed by mean expression of 2-fold or more (log2 fold 
change [lfc] ≥ 1, Figure 4A). Among these genes, 22 were down-
regulated and 34 were upregulated in GATA1s versus WT GATA1 
progenitors (Figure 4C and Supplemental Table 2). Transcripts that 
were reduced in GATA1s progenitors consisted mainly of erythroid 
genes, including those that participate in hemoglobin synthesis 
(HBZ, HBG1, HBE1, AHSP/ERAF, and ALAS2). Among these down-
regulated genes, 19 out of 22 were likely GATA1 targets, as indicat-
ed by ChIP-seq of human peripheral blood– and fetal liver–derived 
erythroblasts (Supplemental Table 2) (PBDE and PBDEFetal, The 
ENCODE Project; ref. 27). This frequency is about twice the value 
expected by chance (binomial test, P = 10–4). Enrichment for GATA1 
binding around these genes indicated that their reduced expression 
in GATA1s progenitors might be a direct consequence of GATA1 
truncation. Thus, GATA1s may fail to efficiently bind or activate 
erythroid gene targets that are normally regulated by WT GATA1. 
Although 20 out of 34 genes upregulated in T21/GATA1s cells were 
bound by GATA1 in human PBDE and/or PBDEFetal cells (Supple-
mental Table 2), this was not significantly different from random 
expectation (1.3-fold enrichment; binomial test, P = 0.084).
We used Gene Set Enrichment Analysis (GSEA) (28, 29) 
to examine more broadly the lineage specificity of differen-
tially expressed genes. Specifically, we compared the sets of 119 
downregulated and 154 upregulated genes (the 273 differentially 
expressed genes at BH‑FDR < 0.1) in GATA1s progenitors, with 
published lists of genes ordered by their differential expression in 
distinct hematopoietic lineages (30). The set of genes downregu-
lated in GATA1s mutant progenitors was preferentially expressed 
in erythroid as compared with myeloid and megakaryocytic lin-
eages (P < 0.05; Figure 4, B and C, and Supplemental Figure 4). 
Genes upregulated in GATA1s progenitors were significantly 
enriched for megakaryocytic (P < 0.05; Figure 4, B and C, and 
Figure 5. PCA identifies lineage signatures and reveals heterogeneity within progenitor cell populations. Single cells within CD43+CD41+CD235+ hemato-
poietic progenitor populations derived from WT and mutant iPSCs were purified by flow cytometry and analyzed for gene expression by qPCR. For compari-
son, committed erythroid (CD41–CD235+), myeloid (CD45+CD18+), and megakaryocytic (CD41+CD42+) cells generated from WT iPSCs were purified and analyzed 
in parallel. (A) Numbers of analyzed single cells of each genotype (total 755 single cells). WT lineage committed cells: myeloid (myelo), megakaryocytic, and 
erythroid (ery). CD43+CD41+CD235+ progenitor genotypes: euploid/WT GATA1, euploid/GATA1s, T21/WT GATA1, T21/GATA1s. (B) PCA on 170 committed ery-
throid (red), myeloid (green), and megakaryocytic (blue) cells based on expression patterns of 94 genes (right plot). PC loadings obtained from this analysis 
(right) were used to project 274 GATA1s (purple) and 311 WT GATA1 (black) progenitor cells onto PC1 and PC2 (left). (C) Smooth kernel density estimate of PC1 
scores of GATA1s (purple line) and WT GATA1 progenitors (black line). Purple and black vertical lines represent mean PC1 scores. Shaded areas around the 
mean correspond to 90% confidence interval for the mean. *P = 10–13 (Mann-Whitney U test). (D) Violin plots showing distributions of single-cell expression 
levels of 3 genes that were upregulated (left) and 3 genes that were downregulated (right) in GATA1s vs. WT GATA1 progenitors in 5 cell types analyzed (FDR 
< 0.05; Mann-Whitney U test followed by BH-FDR correction). lfc, lfc of mean expression between GATA1s and WT GATA1 progenitors.
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Supplemental Figure 4) and myeloid lineages (P = 0.071; Figure 4, 
B and C; P = 0.006 for GSEA performed on 34 genes that were ≥ 
2-fold upregulated, Supplemental Figure 4). GATA1 contributes to 
lineage bias of multipotent progenitors by activating erythroid and 
megakaryocytic targets while repressing a myeloid transcriptional 
program (reviewed in ref. 31). These observations suggest that in 
hematopoietic progenitor cells, GATA1s downregulates an ery-
throid transcriptional program and induces a myelo-megakaryo-
cytic program. Transcriptome comparison of euploid GATA1s ver-
sus WT GATA1 iPSC–derived progenitors demonstrated a similar 
pattern, suggesting that these effects of GATA1s are independent 
of T21 (Supplemental Figure 5).
Single-cell gene expression analysis reveals heterogeneity in WT 
GATA1 and GATA1s progenitor populations. Our analysis of tran-
scriptomes in progenitor populations showed that GATA1s muta-
tions confer a strong bias toward myelo-megakaryocytic tran-
scription. However, individual phenotypically matched stem 
and progenitor cells exhibit considerable heterogeneity in gene 
expression (32, 33). Thus, subpopulations of cells within our iPSC-
derived progenitor pools could exhibit different fate biases. To 
investigate this, we used quantitative real-time PCR (qPCR) to 
compare expression levels of 91 selected hematopoietic genes 
and 3 housekeeping genes (Supplemental Table 3) in 755 individ-
ual, flow-cytometry–purified CD43+CD41+CD235+ iPSC–derived 
progenitors. Input cell genotypes included GATA1s (84 euploid 
+ 190 T21 = 274 cells) and WT GATA1 (115 euploid + 196 T21 = 
311 cells) iPSC–derived progenitors. As controls, we examined 
euploid/WT GATA1 lineage–committed erythroid (CD41–CD235+, 
n = 57), megakaryocytic (CD41+CD42+, n = 61), and myeloid 
(CD45+CD18+, n = 52) cells (Figure 5A).
The expression profiles of the single cells can be represented 
as 755 data points (one per cell) in a 94-dimensional gene space. 
We used principal component analysis (PCA) to identify weighted 
combinations of gene expression that capture the major differenc-
es among erythroid, megakaryocytic, and myeloid lineages. Each 
weighted combination is a principal component (PC), which is a 
vector composed of 94 coefficients (also called loadings) related 
to the contribution of each gene’s expression to the PC (Figure 5B). 
Figure 6. Single-cell gene expression analysis predicts erythroid-to-myeloid fate bias in GATA1s mutant progenitors. (A) Projections of expression 
patterns of iPSC-derived committed cells (filled circles in both plots) and CD43+CD41+CD235+ progenitors expressing WT GATA1 (left, open diamonds) or 
GATA1s (right, open diamonds) onto linear discriminants 1 and 2 (LD1 and LD2). Projections for each cell are colored according to the classification obtained 
from LDA using a probability threshold of greater than 0.90. Classifications of committed cells: erythroid (red circles), megakaryocytic (blue circles), 
myeloid (green circles); classifications of WT GATA1 (left) or GATA1s (right) progenitors: predicted erythroid (pEry) (red diamonds), predicted megakaryo-
cytic (pMeg) (blue diamonds), predicted myeloid (pMyelo) (green diamonds). Gray diamonds represent progenitors that were unclassified at a probability 
threshold of greater than 0.90. (B) Hierarchical clustering on probabilities of belonging to erythroid, megakaryocytic, or myeloid class assigned by LDA 
to progenitor cells. WT GATA1 or GATA1s progenitors that were assigned to a given class with a probability of greater than 0.90 are represented on 2 heat 
maps on the left, while cells that were unclassified (probability < 0.90) are shown on 2 heat maps on the right. (C) Classification of CD43+CD41+CD235+ 
progenitors using LDA. Plotted are fractions of WT GATA1 and GATA1s progenitor populations (consisting of a total of 311 and 274 single cells, respectively) 
classified into predicted cell fate with a probability of greater than 0.90. The remaining cells are plotted as unclassified. *P < 0.05 (Fisher’s exact test).
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nificantly different (P > 0.05, Figure 6C). Unclassified progenitors 
were heterogeneous, with varying probabilistic preferences, and 
may represent a less-differentiated subpopulation compared with 
classified cells (Figure 6B). In summary, single-cell gene expression 
analysis suggests that GATA1s mutant progenitors are biased toward 
myeloid fates and away from an erythroid fate, relative to a surface 
phenotype-matched WT GATA1 population.
Cell-fate bias predicted by gene expression studies could be 
executed by a few driver genes or by small contributions from 
many genes. We searched for potential driver genes by examining 
the distributions of expression levels for all 94 genes interrogat-
ed among single cells. These distributions differed dramatically 
among the committed myeloid, erythroid, and megakaryocytic lin-
eages, as expected (Figure 5D and Supplemental Figure 6). Com-
parison of WT GATA1 and GATA1s mutant progenitors identified 
40 of 94 differentially expressed genes (BH‑FDR < 0.05; Mann-
Whitney U test followed by BH correction; Supplemental Table 
4, Figure 5D, and Supplemental Figure 6). Importantly, for most 
of these genes (36 of 40), expression in WT GATA1 progenitors is 
shifted toward that of erythroid cells, while expression in GATA1s 
progenitors favored myeloid and/or megakaryocytic fates (Figure 
5D and Supplemental Figure 6). Moreover, many of the differ-
entially expressed genes exhibited only small changes in mean 
expression (25 of 40 less than 2-fold change; Supplemental Table 
4). Thus, the aggregate of small changes in expression of many 
hematopoietic genes may cause erythroid–to–myelo-megakaryo-
cytic lineage bias of GATA1s progenitors.
Defective erythropoietic activity of GATA1s in murine megakaryo-
cyte-erythroid progenitor–like cells. We compared the properties of 
GATA1fl and GATA1s in GATA1– megakaryocyte-erythroid (G1ME) 
cells, a megakaryocyte-erythroid progenitor–like (MEP-like) line 
derived from Gata1– ESCs (34). Four days after transduction by 
GATA1fl-expressing retrovirus, G1ME cells differentiated into 
Ter119+ erythroblasts and GpIb+ (CD42) megakaryocytes (Figure 7, 
A and B), as reported previously (34). However, erythropoiesis was 
impaired after expression of GATA1s, as evidenced by reduced pro-
portion of Ter119+ cells (Figure 7A) and stalled erythroid maturation 
revealed by histological staining (Figure 7B). In contrast, GATA1s 
induced an increased proportion of normal-appearing megakaryo-
cytes (Figure 7, A and B). Importantly, GATA1fl and GATA1s were 
expressed at similar levels in G1ME cells (Figure 7C; see complete 
unedited blots in the supplemental material). Thus, the observed 
differences in the hematopoietic activities of these 2 isoforms are 
not due to dosage discrepancies among the virally encoded pro-
teins. Overall, these complementation studies in G1ME cells are 
consistent with the phenotypes of patients harboring germline 
GATA1s mutations (2, 3) and our in vitro differentiation studies of 
GATA1s patient-derived iPSCs (Figures 1 and 2).
Loss of the N-terminus selectively decreases GATA1 binding at ery-
throid genes. Given that other germline GATA1 mutations outside 
the DNA-binding domain affect the ability of GATA1 to bind target 
sites in vivo (35–38), we investigated whether loss of the GATA1 
N-terminus also impairs chromatin occupancy. We performed 
ChIP-seq on G1ME cells 42 hours after retroviral transfer of HA-
tagged GATA1fl or GATA1s cDNAs. At this time point, there was 
no apparent difference in the cell-surface phenotypes between 
GATA1fl- and GATA1s-expressing cells (Figure 7A, top row).
Notably, the first 2 PCs — PC1 and PC2 — accounted for 65% of 
the variance in the data. Projection of the expression patterns from 
committed cells onto the plane of PC1 and PC2 resulted in clear 
clustering of the 3 reference cell types (Figure 5B), showing that 
PC1 and PC2 can distinguish specific lineage signatures of ery-
throid, megakaryocytic, and myeloid cells.
Expression profiles from individual WT GATA1 and GATA1s 
progenitors projected onto PC1 and PC2 were distributed heter-
ogeneously among the 3 differentiated cell lineages (Figure 5B), 
with some progenitor cells located closer to one of the mature cell 
types and others located more equally among the 3 reference cell 
types. This heterogeneity suggested that the PC1 and PC2 scores 
could also be used to estimate the likelihood of a single progenitor 
differentiating toward erythroid, megakaryocytic, or myeloid lin-
eages. Although the distributions of WT GATA1 and GATA1s pro-
genitors overlapped, cells expressing GATA1s were shifted along 
PC1 toward myeloid and megakaryocytic reference cells relative 
to WT GATA1, as illustrated by density plots of PC1 scores (i.e., 
projections of expression patterns of each cell along PC1) (Figure 
5, B and C, P = 10–13, Mann-Whitney U test). Examples of genes 
that are differentially expressed in WT GATA versus GATA1s 
mutant progenitors are shown in Figure 5D.
We used PC1 and PC2 as lineage signatures within a linear dis-
criminant analysis (LDA) to assign to each progenitor cell a probabil-
ity of belonging to each of the 3 cell types. Biologically, these prob-
abilities can be used to approximate the likelihood that a particular 
progenitor cell will differentiate toward a given lineage and thus infer 
its developmental potential within 4 categories: erythroid, mega-
karyocytic, myeloid, or unclassified (probability threshold > 0.90) 
(Figure 6, A and B). Compared with WT GATA1 progenitors, cells 
expressing GATA1s were much less frequently classified as likely 
to differentiate toward erythroid (P = 6 × 10–7, Fisher’s exact test) 
and more likely to be classified myeloid (P = 5 × 10–4; Figure 6C). In 
contrast, the cell-fate predictions between WT GATA1 and GATA1s 
progenitors for megakaryocytic fate and unclassified were not sig-
Figure 7. Loss of the N-terminus selectively inhibits GATA1 binding to 
erythroid genes in Gata1– MEPs. (A) Flow cytometry of G1ME cells at 42 
and 96 hours after transduction with HA-GATA1fl or HA-GATA1s. Numbers 
denote percentage of total cells in the indicated quadrant. (B) May-Grün-
wald-Giemsa staining of G1ME-derived erythroblasts (left) and megakaryo-
cytes (right) 96 hours after transduction. Scale bars: 20 μm. (C) Western 
blot at 42 hours after transduction showing expression of HA-GATA1fl and 
HA-GATA1s relative to β-actin. ND, not determined. (D) Genome-wide ChIP-
seq binding signals of GATA1fl and GATA1s at 42 hours after transduction. 
Plotted are mean read counts (n = 2 replicates each). non-DB, nondiffer-
entially bound (gray dots); DB, differentially bound sites (blue and cyan; 
FDR < 0.1). (E) Functional enrichme nt analysis using GREAT. Plotted are 
significance values for top 10 mouse phenotype and GO biological process 
enrichment terms, classified as erythroid, megakaryocytic, myeloid, other 
hematopoietic, or cardiovascular and other. List of terms can be found in 
Supplemental Table 5. (F) GATA1 binding at the β-globin locus. ChIP-seq 
tracks, top to bottom: GATA1fl and GATA1s in G1MEs, GATA1fl in primary 
mouse erythroblasts and megakaryocytes (42). Rectangles above tracks: 
size of binding sites analyzed in differential binding analysis; gray, non-DB; 
blue, DB. (G) Anti-HA ChIP at selected GATA1-binding sites in G1MEs shown 
as ratio of GATA1s to GATA1fl occupancy ± SEM (n = 4). *Ratio significantly 
different than 1 at P < 0.05 (2-tailed Student’s t test). IgG GATA1s and IgG 
GATA1fl controls for nonspecific binding.
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anemia in gene-targeted mouse embryos (12, 13) and in euploid 
patients with hypoplastic anemia, including some who were 
assigned a diagnosis of DBA (2, 3). Here, we used patient-derived 
iPSCs and mouse ESCs to confirm that GATA1s mutations impair 
erythropoiesis and investigated the underlying mechanisms. A 
recent study used gene-editing and chromosome-transfer tech-
niques to show that a GATA1s mutation inhibits the erythropoietic 
capacity of euploid and T21 human ESCs (43). Our current findings 
confirm this result in iPSCs generated from multiple patients and 
identify underlying mechanisms. Specifically, we show that loss 
of the amino-terminus decreases binding to selective sites within 
erythroid genes and biases hematopoietic output toward cells of 
megakaryocytic and myeloid fates at the expense of erythropoiesis.
GATA1 regulates hematopoietic cell fates by activating lineage-
specific genes and repressing those of alternate cell types (31). Pre-
vious loss-of-function and overexpression studies demonstrated 
that GATA1 stimulates differentiation of multipotent progenitors 
toward erythroid fate (44–48) and also acts as a survival/matura-
tion factor for committed erythroblasts (26, 49). The reduced eryth-
ropoietic activities of GATA1s demonstrated in the current study 
could occur through either or both mechanisms. Experiments in 
bipotential G1ME cells indicate that GATA1s is deficient in both pro-
motion of erythroid differentiation of bipotential progenitors (Fig-
ure 7A) and maturation of committed erythroid progenitors (Fig-
ure 7B) compared with GATA1fl. It is more difficult to distinguish 
between these mechanisms in iPSC differentiation cultures, since 
CD43+CD41+CD235+ progenitors generally give rise to relatively 
few multilineage colonies (refs. 15, 50, 51, and Figure 2A), which 
limited our ability to investigate the effects of GATA1s on lineage 
determination. Thus, we cannot ascribe the myelo-megakaryocytic 
lineage bias observed for the GATA1s CD43+CD41+CD235+ popula-
tion unambiguously to either a shift in lineage choice or altered sur-
vival/proliferation of monolineage-committed progenitors. We did 
find that WT GATA1 and GATA1s iPSCs produce similar numbers of 
CD43+CD41+CD235+ progenitors, and thus, if the loss of erythroid 
potential resulted from a decrease in erythroid-committed progeni-
tors, then the myelo-megakaryocytic progenitors replaced them. 
The lineage signatures derived from expression analysis of individ-
ual progenitor cells reveal a subpopulation of cells that are not read-
ily classified as likely to differentiate t o 1 of the 3 lineages. These 
less-differentiated progenitors could have multilineage potential, 
but such an assignment awaits formal fate-mapping studies.
Both WT GATA1 and GATA1s produce dosage-dependent 
effects (9, 25, 26). GATA1s mutations typically reduce overall 
GATA1 protein output. Thus, it is possible that GATA1s functions 
normally, but is expressed at insufficient levels for optimal erythro-
poiesis. Supporting this, mutant mice expressing modestly reduced 
levels of WT GATA1 protein are anemic (25, 26), and transgenic 
rescue with high levels of GATA1s restores erythropoiesis in a dif-
ferent strain of Gata1-deficient mice (9). Moreover, we show that 
enforced expression of ectopic GATA1s enhances erythropoiesis 
in iPSC-derived progenitors from patients with GATA1s mutations 
(Figure 3). Alternatively, the GATA1 N-terminus may mediate 
unique functions specifically in erythroid cells. In support, ectopic 
GATA1s is inferior to an equivalent level of GATA1fl for promoting 
erythropoiesis in GATA1s iPSC–derived hematopoietic progenitors 
(Figure 3) and in bipotential Gata1– G1ME cells (Figure 7).
Genome-wide analysis of 16,231 binding sites occupied by 
GATA1fl and/or GATA1s in G1ME cells identified 4,721 sites that 
were differentially bound (FDR < 0.1; edgeR analysis implemented 
by DiffBind package in R; refs. 39, 40) (Figure 7D). This included 
2,106 sites that were bound more by GATA1fl than GATA1s and 
2,615 sites that were bound more by GATA1s than GATA1fl. We 
used Genomic Regions Enrichment of Annotations Tool (GREAT) 
to investigate the functional implications of differential DNA bind-
ing by GATA1s (> 2-fold difference in binding signal) (41). Impor-
tantly, genes assigned to sites bound more by GATA1fl than GATA1s 
were highly enriched for terms associated with erythroid functions 
(Figure 7E and Supplemental Table 5). Consistent with these find-
ings, genome-wide microarray transcriptome analysis comparing 
mean gene expression levels between cells expressing GATA1s ver-
sus GATA1fl at 42 hours after transduction revealed downregula-
tion of an erythroid program and upregulation of a megakaryocytic 
program in GATA1s-expressing cells (Supplemental Figure 7). We 
confirmed the decreased binding of GATA1s relative to GATA1fl 
at key erythroid regulatory regions by ChIP-qPCR in independent 
transductions of G1ME cells (Figure 7G) and observed decreased 
expression of erythroid GATA1 target genes (Supplemental Figure 
8). Thus, we conclude that the erythropoietic defect observed for 
the loss of the GATA1 NAD results at least in part from decreased 
binding of GATA1s at selected sites regulating erythroid genes.
In contrast, the increased binding associated with loss of the 
GATA1 NAD occurs almost exclusively at sites with weak bind-
ing by GATA1s (Figure 7D and Supplemental Figure 9). While the 
presumptive target genes assigned to those sites were enriched for 
nonerythroid terms, including megakaryocytic and myeloid, these 
enrichments had lower statistical significance than erythroid tar-
gets associated with decreased binding of GATA1s (Figure 7E). 
Restricting the analysis to sites with stronger binding reduces the 
number of terms enriched for the presumptive targets (Supple-
mental Figure 9). Furthermore, the ChIP-qPCR results showed 
nonsignificant differences between GATA1fl and GATA1s binding 
at a subset of known megakaryocytic regulatory regions (Figure 
7G), although expression of some of the tested megakaryocytic 
genes increased (Supplemental Figure 8).
While GATA1s binds differentially relative to GATA1fl at many 
sites, we observed equivalent occupancy by GATA1fl and GATA1s 
at many other sites, including some sites regulating erythroid 
genes. This demonstrates that the N-terminus facilitates DNA 
interactions selectively, even within the same lineage. For exam-
ple, GATA1s binding was decreased at the HS2 and HS3 regula-
tory regions of the Hbb-y locus compared with GATA1fl (FDR < 
0.1), but was equivalent at the HS1 site (Figure 7F). These β-globin 
locus target sites are not bound by GATA1fl in megakaryocytes 
(ChIP-seq track from ref. 42). Together, these data show that loss 
of the GATA1 N-terminus decreases chromatin occupancy at spe-
cific sites within erythroid target genes, which likely contributes to 
erythropoietic deficiencies mediated by the GATA1s protein.
Discussion
GATA1s mutations that remove amino acids 1–83 of the full-length 
GATA1 protein via alternate splicing and use of an internal initia-
tion codon were first identified in DS-associated AMKL and TMD 
(5). More recently, similar mutations were discovered to cause 
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myelopoiesis and megakaryopoiesis observed in GATA1s iPSCs 
regardless of karyotype diverge from phenotypes of individuals 
with germline GATA1s mutations that are associated with anemia 
and neutropenia. Induction of adult-type “definitive” hematopoie-
sis in iPSC cultures may be required to better recapitulate all clinical 
phenotypes. Overall, our current findings show that patient-derived 
iPSCs recapitulate many clinical aspects of germline GATA1s muta-
tions and provide a model system for better defining the role of the 
GATA1 N-terminus in human erythropoiesis.
While the current study focuses on the role of GATA1s mutations 
in erythropoiesis, our findings also provide insights into how these 
mutations interact with T21. Previous work has shown that T21 aug-
ments erythropoiesis in primary fetal cells (61–63) and iPSCs (18, 
64). Here, we confirm these findings in T21/WT GATA1 iPSCs and 
demonstrate that GATA1s overrides the erythropoietic effects of T21 
in isogenic double-mutant T21/GATA1s iPSCs derived from 2 differ-
ent patients with TMD. In addition, we show that GATA1s enhances 
human megakaryocyte and myeloid expansion, which likely contrib-
utes to the development of DS-associated myeloproliferative disor-
ders. A LXCXE motif within the N-terminus of GATA1 (amino acids 
81–85) binds Rb-E2F transcription factor family members, which 
inhibits the expression of genes that stimulate cell proliferation (56, 
65). Studies of GATA1 alleles in DS‑TMD patients, including rare 
cases with mutations that produce internal protein deletions (66), 
map a minimal disease-associated domain to within amino acids 
74–83, which includes the Rb-binding motif. It will be interesting to 
determine whether this region also facilitates erythroid differentia-
tion or, alternatively, whether this effect can be uncoupled from the 
antiproliferative actions of GATA1 on myelopoiesis and megakaryo-
poiesis via distinct mutations affecting the N-terminus.
Methods
Generation of iPSCs. Mononuclear cells were infected with pHage2-
CMV‑RTTA‑W and pHage-Tet-hSTEMMCA-loxP virus with human 
OCT4, SOX2, KLF4, or MYC, as previously performed (17, 18). Repro-
gramming details and characterization methods are provided in Sup-
plemental Methods.
Hematopoietic differentiation. iPSC EB formation, hematopoi-
etic colony assays, liquid culture assays, lentiviral infection, and 
flow cytometry were performed as previously described (18) as and 
described in Supplemental Methods.
Cell line culture. G1ME cells were generated, cultured, and geneti-
cally manipulated as described by our laboratory (34). The MSCV-
based retroviral vector MIGR1‑GFP was used to express HA-tagged 
murine GATA1 or GATA1s in G1ME cells.
Western blot. Nuclear extracts were prepared according to standard 
methods, fractionated on sodium dodecyl sulfate–2% polyacrylamide 
gels, and transferred to nitrocellulose membranes by electroblotting. 
Antibodies included anti-human GATA1 (ab11852, Abcam), HA (sc-805, 
Santa Cruz Biotechnology Inc.), and actin (A3854, Sigma-Aldrich). Band 
intensities were quantified using ImageJ (http://imagej.nih.gov/ij/).
qPCR. RNA was isolated with Trizol (Invitrogen) or the RNeasy kit 
(QIAGEN), complementary DNA prepared by the oligo(dT) method 
(Invitrogen), and PCR quantified using SYBR green (Roche) on a ViiA7 
(Life Technologies). Expression was normalized to cyclophilin, Gapdh, 
or β-actin, and relative quantification determined by the comparative 
Ct method. See Supplemental Methods for primer sequences.
Considering our current findings and prior studies of others, 
GATA1s mutations likely cause anemia both by reducing overall 
GATA protein expression and by favoring the production of a func-
tionally impaired form of the transcription factor. Our work pro-
vides mechanistic insights into the latter by showing that the loss 
of GATA1 N-terminus decreases binding to erythroid target genes. 
GATA1s mutations could inhibit erythropoiesis by altering the 
expression of 1 key lineage-determining gene or through aggre-
gate effects on multiple genes. Supporting the latter, we show that 
individual mutant progenitor cells exhibit small but significant 
changes (BH‑FDR < 0.05) in the expression of multiple key lineage 
regulators, including KLF1, GATA2, RUNX1, and CEBPA.
How the N-terminus regulates GATA1 chromatin occupancy to 
enhance erythroid gene expression represents an interesting prob-
lem for future studies. GATA1 binds DNA directly via subdomains 
of its 2 zinc fingers, most importantly the C-finger (52, 53). However, 
several disease-associated amino acid substitutions within the N-fin-
ger inhibit GATA1 binding to target genes in vivo, yet have no effect 
on in vitro binding to naked DNA templates. These regions of the 
N-finger do not interact with DNA directly, but rather are believed to 
promote GATA1 chromatin occupancy by recruiting essential cofac-
tors, including FOG1 and the TAL1/LMO2/LDB1 complex (35, 38). 
Similarly, loss of the Kruppel-like factor 3 transcription N-terminus, 
which also does not bind DNA directly, alters chromatin occupancy 
selectively at a subset of in vivo target genes in mouse embryonic 
fibroblasts (54). Taken together, our current findings suggest that 
interactions between currently unidentified cofactors and the GATA1 
N-terminus facilitate chromatin occupancy specifically at erythroid 
genes. RUNX1 and the retinoblastoma protein (Rb) bind the GATA1 
N-terminus (55, 56). However, loss of RUNX1 in hematopoietic pro-
genitors impairs megakaryopoiesis, but not erythropoiesis (reviewed 
in ref. 57). Rb facilitates terminal maturation of erythroid precursors 
(reviewed in ref. 58), but has no known role in their lineage commit-
ment. Thus, additional proteins likely modulate the erythropoietic 
functions of GATA1 through interactions with its N-terminus.
GATA1s mutations have overlapping and distinct effects on 
hematopoiesis in humans and mice. In mice, Gata1s mutations 
inhibit primitive-type (yolk sac derived) erythropoiesis, resulting in 
partial embryonic lethality (12, 13), but postnatal hematopoiesis is 
normal. In contrast, similar mutations in humans cause erythroid 
hypoplasia and anemia throughout life (2, 3). In the current study, 
we used iPSC in vitro hematopoietic differentiation protocols that 
generate erythroid cells expressing mainly embryonic type globins 
(ζ and ε), thereby resembling yolk sac–type hematopoiesis. These 
data, taken together with murine studies, suggest that some human 
embryos with GATA1s mutations may not survive to birth. Indeed, 
classical DBA caused by heterozygous mutations in ribosomal pro-
tein genes can cause hydrops fetalis and in utero demise (59, 60). 
These clinical observations predict that iPSCs from GATA1s mutant 
patients will exhibit defective fetal liver/bone marrow–type “defini-
tive” erythropoiesis. Currently, methods to produce adult-type 
definitive erythroblasts from human iPSCs are suboptimal, particu-
larly for quantitative comparative studies between different mutant 
and control lines. However, our preliminary experiments indicate 
that EBs derived from WT human iPSCs, but not GATA1s iPSCs, 
generate erythroblasts expressing definitive-type globins (γ and 
β) after prolonged culture (> 30 days) (not shown). The enhanced 
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Microarray transcriptome analysis. RNA was isolated and hybrid-
ized to Affymetrix HuGene 1.0 ST (human iPSC-derived progenitors) 
or Affymetrix Mouse Genome 430 2.0 Microarrays (mouse G1ME 
cells at 42 hours after transduction with GATA1 or GATA1s). To obtain 
gene expression values, raw intensity values from Affymetrix CEL 
data files were processed using the robust multichip average (RMA) 
method (67), implemented by the Bioconductor R “oligo” (HuGene 
1.0 ST arrays) or “affy” (Mouse Genome 430 2.0 arrays) package 
(68–70). All original microarray data were deposited in the NCBI’s 
Gene Expression Omnibus (GEO GSE61933). See Supplemental 
Methods for details on bioinformatics analysis.
Single-cell gene expression analysis. Preamplified cDNA from sorted 
single cells was loaded onto the Fluidigm BioMark 96.96 Dynamic 
Array chips according to the manufacturer’s instructions. See Supple-
mental Methods for details on data processing and bioinformatics 
analysis as well as Supplemental Table 6 for raw and normalized single-
cell gene expression data.
ChIP. ChIP was performed as described (71) with anti-HA (sc-
805; Santa Cruz Biotechnology Inc.) antibody. For ChIP-qPCR, DNA 
was quantified by qPCR with SYBR Green on a ViiA7. See Supplemen-
tal Methods for primer sequences. ChIP-seq libraries were prepared 
as outlined for Illumina’s TruSeq ChIP Sample Prep Kit (IP‑202-
1012), except that the libraries were size selected using Agencourt 
SPRIselect Beads for an average size of approximately 300 to 325 bp 
prior to PCR amplification. Libraries were sequenced on the Illumina 
HiSeq2000. Sequence reads were mapped to the reference mouse 
genome (NCBI37/mm9, July 2007) using Bowtie 1.0.0. ChIP-seq 
peaks were called using MACS 1.3.7.1. All ChIP-seq data were depos-
ited in the NCBI’s Gene Expression Omnibus (GEO GSE61933). See 
Supplemental Methods for details on differential binding analysis.
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